ERBB2 and breast carcinoma: A non-randomized, phase I/II study (NCT02657343) will test maximum tolerated dose (MTD), CBR, ORR, PFS, OS and AEs of Ribociclib in combination with Trastuzumab or T-DM1 for advanced or metastatic HER2+ breast cancer patients.